Graft-Versus-Host Disease

A novel regimen significantly reduced risk for moderate to severe chronic graft-versus-host disease for certain patients who underwent allogeneic hematopoietic stem cell transplantation, according to randomized phase 2 study results.

A multidisciplinary, virtual platform showed preliminary feasibility for reducing distress and improving access for patients with graft-versus-host disease, according to findings published in Transplantation and Cellular Therapy.

The addition of itacitinib to standard graft-versus-host-disease prophylaxis may reduce severe toxicities following haploidentical hematopoietic stem cell transplantation, according to results of a single-arm study.

Aplastic anemia is a bone marrow failure process that presents with pancytopenia and bone marrow hypoplasia/aplasia.

Taking prescribed beta blockers during hematopoietic stem cell transplantation may increase mortality risk due to suppression of signals from nerves that promote bone marrow regeneration, according to study results.

Shernan Holtan, MD, has been named the recipient of 2025 Lukas D. Wartman Award.

Pre-transplant immune checkpoint inhibitors extended survival for patients with relapsed classic Hodgkin lymphoma compared with chemotherapy, according to results of a retrospective study.

SAN DIEGO — Socioeconomic disparities affect access to allogeneic hematopoietic stem cell transplantation for people with acute myeloid leukemia, according to findings presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Increased fiber intake after allogeneic hematopoietic stem cell transplantation appeared linked to improved outcomes, according to study results presented at ASH Annual Meeting and Exposition.

Several hematologists will be honored during this year’s ASH Annual Meeting.